Vaccinology: Horizons Across Disease, Demography and Technology
Jun 04–07, 2025 | Marriott Marquis Washington, DC, Washington, DC, United States
Scientific Organizers:
Rino Rappuoli, Kanta Subbarao, Laurence Zitvogel and Firdausi Qadri
Livestream
In Person
On Demand
Jun 04–07, 2025 | Marriott Marquis Washington, DC, Washington, DC, United States
Scientific Organizers:
Rino Rappuoli, Kanta Subbarao, Laurence Zitvogel and Firdausi Qadri
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandFundraising
Merchandise Options
Registration Options
Wednesday, June 4, 2025
Booking Function
Registration
7:00–8:00 PM
Foyer
Thursday, June 5, 2025
Registration Continues
7:00–8:30 AM
Foyer
Breakfast
7:30–8:30 AM
Independence Salons EFGH
Poster Setup
8:00–8:30 AM
Independence Salons EFGH
Poster Viewing
8:00–5:00 PM
Independence Salons EFGH
Welcome and Keynote Address
8:30–9:30 AM
Independence Salons ABCD
* Rino Rappuoli, Fondazione Biotecnopolo di Siena
Session Chair
Session Chair
Peter J. Hotez, Baylor College of Medicine
Vaccines and Immunizations in a Time of Global Boiling, Megacities, and Antiscience
Vaccines and Immunizations in a Time of Global Boiling, Megacities, and Antiscience
Why Should I Trust You? Podcast Introduction
9:30–9:40 AM
Independence Salons ABCD
Learning the Molecular Immunology of mRNA Vaccines
9:40–11:45 AM
Independence Salons ABCD
* Bali Pulendran, Stanford University School of Medicine
Comparative Responses to mRNA and Adjuvanted Vaccines
Comparative Responses to mRNA and Adjuvanted Vaccines
Ali H Ellebedy, Washington University School of Medicine
B Cell Responses to mRNA Vaccination/Induction of New Epitopes
B Cell Responses to mRNA Vaccination/Induction of New Epitopes
* Rita Carsetti, Bambino Gesù Children Hospital
Early Immune Responses to Vaccination
Early Immune Responses to Vaccination
Michela Locci, University of Pennsylvania
Short Talk: Distinct Components of Nucleoside-modified Messenger RNA Vaccines Cooperate to Instruct Efficient T Follicular Helper Cell Responses
Short Talk: Distinct Components of Nucleoside-modified Messenger RNA Vaccines Cooperate to Instruct Efficient T Follicular Helper Cell Responses
Coffee Break
10:10–10:30 AM
Foyer
Lunch
11:45–12:45 PM
Independence Salons EFGH
Poster Session 1
12:15–2:30 PM
Independence Salons EFGH
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Independence Salons ABCD
* Wolfgang W Leitner, National Institute of Allergy and Infectious Diseases, NIH, DHHS
Session Chair
Session Chair
* Catherine J Wu, Dana-Farber Cancer Institute
Session Chair
Session Chair
Artem Ashurov, University Hospital of Cologne
Remote Presentation: Structural Characterization of Antibodies for Synergistic HCMV Neutralization
Remote Presentation: Structural Characterization of Antibodies for Synergistic HCMV Neutralization
Namit Chaudhary, Scripps Research
Alumina-coated Microparticles Enable Extended Antigen Delivery of HIV Immunogens in a Single Shot
Alumina-coated Microparticles Enable Extended Antigen Delivery of HIV Immunogens in a Single Shot
Grace Freeman, National Institutes of Health
Isolation of Monoclonal Antibodies against H5Nx Influenza Viruses from Individuals Immunized with a Monovalent H5N1 Vaccine
Isolation of Monoclonal Antibodies against H5Nx Influenza Viruses from Individuals Immunized with a Monovalent H5N1 Vaccine
Grace Hendricks, University of Washington
Computationally Designed mRNA-launched Protein Nanoparticle Immunogens as an Integrated Vaccine Platform
Computationally Designed mRNA-launched Protein Nanoparticle Immunogens as an Integrated Vaccine Platform
Fnu Alakesh, Stanford University
Understanding the Immune Landscape behind TLR-based Hydrogel Vaccines
Understanding the Immune Landscape behind TLR-based Hydrogel Vaccines
Sacha Zinn, Garvan Institute of Medical Research
Tailoring SARS-CoV-2 Humoral Responses using mRNA-encoded mAbs
Tailoring SARS-CoV-2 Humoral Responses using mRNA-encoded mAbs
Giovanna de Brito Carneiro, Instituto Butantan
CyaA Vector Carrying Fragments of the Pneumococcal Surface Protein A as a Vaccine Candidate against Streptococcus Pneumoniae
CyaA Vector Carrying Fragments of the Pneumococcal Surface Protein A as a Vaccine Candidate against Streptococcus Pneumoniae
Hervé Besançon, University of California, San Diego
A STING-Adjuvanted Outer Membrane Vesicle Nanoparticle Vaccine Against Klebsiella pneumoniae
A STING-Adjuvanted Outer Membrane Vesicle Nanoparticle Vaccine Against Klebsiella pneumoniae
Coffee Available
4:30–5:00 PM
Foyer
Vaccines, Emerging Reality in Cancer Therapy
5:00–7:00 PM
Independence Salons ABCD
* Laurence Zitvogel, Institut Gustave Roussy
Session Chair
Session Chair
Catherine J Wu, Dana-Farber Cancer Institute
Personalized Cancer Vaccines: Updates and Encouraging Results
Personalized Cancer Vaccines: Updates and Encouraging Results
* Ira Mellman, Parker Institute for Cancer Immunotherapy
Combining Checkpoints Inhibitor Immunotherapy and Personalized Vaccines
Combining Checkpoints Inhibitor Immunotherapy and Personalized Vaccines
Pirooz Zareie, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne
Defining TRM Cell Fate: The Combined Influence of TCR Signaling and Tissue Instruction
Defining TRM Cell Fate: The Combined Influence of TCR Signaling and Tissue Instruction
Shuang Chen, UT Southwestern Medical Center
Short Talk: Systemic STING Nanovaccine for HPV-Induced Cancer Therapy
Short Talk: Systemic STING Nanovaccine for HPV-Induced Cancer Therapy
Xinbo Gao, Tianjin Medical University
Short Talk: Enhancing Pancreatic Cancer Vaccines with OX40 Agonist and PD-1 Inhibitor to Synergize Antitumor Immunity and Reshape the Immune Microenvironment
Short Talk: Enhancing Pancreatic Cancer Vaccines with OX40 Agonist and PD-1 Inhibitor to Synergize Antitumor Immunity and Reshape the Immune Microenvironment
On Own for Dinner
7:00–8:00 PM
Friday, June 6, 2025
Breakfast
7:30–8:30 AM
Independence Salons EFGH
Preparing for New Pandemics and Emerging Infections
8:30–11:30 AM
Independence Salons ABCD
* Galit Alter, Ragon Institute of MGH, MIT, and Harvard
Session Chair
Session Chair
Penny L Moore, University of the Witwatersrand and National Institute for Communicable Diseases
Remote Presentation: Views from the African Continent
Remote Presentation: Views from the African Continent
* Kanta Subbarao, Université Laval
WHO Strategy, One Health Considerations, Equity
WHO Strategy, One Health Considerations, Equity
Cristina Cassetti, Independent Expert, Retired Division Deputy Director at NIAID
Prototype Vaccines
Prototype Vaccines
Rino Rappuoli, Fondazione Biotecnopolo di Siena
An Institute for Pandemic Preparedness
An Institute for Pandemic Preparedness
Masaru Kanekiyo, NIAID, NIH
Short Talk: A Mosaic Nanoparticle Displaying Stabilized Stem Trimers of Multiple Hemagglutinin Subtypes Elicits Broadly Cross-Reactive and Protective Immunity in Nonhuman Primates
Short Talk: A Mosaic Nanoparticle Displaying Stabilized Stem Trimers of Multiple Hemagglutinin Subtypes Elicits Broadly Cross-Reactive and Protective Immunity in Nonhuman Primates
Nitesh Mishra, The Scripps Research Institute
Short Talk: Machine Learning Enabled Conformational Mapping Optimizes Lassa Virus Vaccine Candidates
Short Talk: Machine Learning Enabled Conformational Mapping Optimizes Lassa Virus Vaccine Candidates
Coffee Break
9:30–9:50 AM
Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Independence Salons ABCD
Poster Setup
11:30–1:00 PM
Independence Salons EFGH
On Own for Lunch
11:30–2:45 PM
Poster Viewing
1:00–10:00 PM
Independence Salons EFGH
Career Roundtable
2:00–3:30 PM
Independence Salons ABCD
Rita Carsetti, Bambino Gesù Children Hospital
Head, B cell Lab
Head, B cell Lab
Mihai L Azoitei, Duke University
Associate Professor
Associate Professor
Meron Mengistu, Gilead Sciences
Principal Scientist
Principal Scientist
Swapnika Ramu, Cell Press
Senior Scientific Editor
Senior Scientific Editor
Panel Discussion: Transforming Early-Stage Vaccine Development
3:45–4:30 PM
Independence Salons ABCD
* Rino Rappuoli, Fondazione Biotecnopolo di Siena
Panel Moderator
Panel Moderator
John Tsang, Yale University School of Medicine
Panelist
Panelist
Neil P King, University of Washington
Panelist
Panelist
Nicole Lurie, Coalition for Epidemic Preparedness Innovations - CEPI
Panelist
Panelist
Coffee Available
4:30–5:00 PM
Foyer
Understanding Mechanistic Immunology to Drive Vaccine Design
5:00–6:30 PM
Independence Salons ABCD
* Michel C. Nussenzweig, HHMI/Rockefeller University
Germinal Center Selection
Germinal Center Selection
* Emanuele Andreano, Fondazione Biotecnopolo di Siena
B Cell Responses
B Cell Responses
Matthew J Wiest, University of Michigan
Short Talk: Heterologous Prime-pull Immunization Strategies for SARS-CoV-2 Drives Enhanced, Long-lived Mucosal and Systemic Cellular and Antibody Responses
Short Talk: Heterologous Prime-pull Immunization Strategies for SARS-CoV-2 Drives Enhanced, Long-lived Mucosal and Systemic Cellular and Antibody Responses
Vishal N Rao, Icahn School of Medicine at Mount Sinai
Short Talk: Convergent and Clonotype-enriched Mutations Drive Affinity Maturation of a Public Antibody
Short Talk: Convergent and Clonotype-enriched Mutations Drive Affinity Maturation of a Public Antibody
Social Hour with Lite Bites
6:30–7:30 PM
Independence Salons EFGH
Poster Session 2
7:30–10:00 PM
Independence Salons EFGH
Saturday, June 7, 2025
Breakfast
7:30–8:30 AM
Independence Salons EFGH
Designing and Evaluating New Vaccines
8:30–11:30 AM
Independence Salons ABCD
Jason S McLellan, The University of Texas at Austin
Structure Based Design
Structure Based Design
Wolfgang W Leitner, National Institute of Allergy and Infectious Diseases, NIH, DHHS
NIAID Vaccine Adjuvant Program and New Trends in Adjuvant Research
NIAID Vaccine Adjuvant Program and New Trends in Adjuvant Research
Galit Alter, Ragon Institute of MGH, MIT, and Harvard
Mechanistic and Non Mechanistic Correlates of Protection
Mechanistic and Non Mechanistic Correlates of Protection
* Florian Krammer, Icahn School of Medicine at Mount Sinai
Development of Broadly Protective Vaccines to Antigenically Variable Viruses
Development of Broadly Protective Vaccines to Antigenically Variable Viruses
* Alessandro Sette, La Jolla Institute for Immunology
The Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential
The Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential
Mihai L Azoitei, Duke University
Short Talk: Development and Validation of Pan-Betacoronavirus Vaccine Candidates that Target the S2 Domain of Spike
Short Talk: Development and Validation of Pan-Betacoronavirus Vaccine Candidates that Target the S2 Domain of Spike
Coffee Break
9:30–9:50 AM
Foyer
Innovations in Vaccine Science: Advancing Precision Medicine
11:30–12:45 PM
Independence Salons ABCD
* Rino Rappuoli, Fondazione Biotecnopolo di Siena
Session Chair
Session Chair
* Cristina Cassetti, Independent Expert, Retired Division Deputy Director at NIAID
Session Chair
Session Chair
Courtney L Page, Wake Forest University School of Medicine
An Influenza HA-expressing mRNA-LNP vaccine induces potent and protective responses in newborn NHP
An Influenza HA-expressing mRNA-LNP vaccine induces potent and protective responses in newborn NHP
Florian W Gegenfurtner, Karolinska Institutet
Antibody Responses to Pneumoviruses Fluctuate During Life – Implications for RSV Vaccination
Antibody Responses to Pneumoviruses Fluctuate During Life – Implications for RSV Vaccination
Murilo Sena Amaral, Instituto Butantan
Protection in Rhesus Macaques Against Schistosoma Mansoni Induced by a Multi-Epitope Vaccine Candidate
Protection in Rhesus Macaques Against Schistosoma Mansoni Induced by a Multi-Epitope Vaccine Candidate
Elizabeth M Villasis, Universidad Peruana Cayetano Heredia
Assessment of the Functional Role of Purified Antibodies from Asymptomatic P. vivax-infected Individuals from the Peruvian Amazon using P. Knowlesi in vitro Culture Model
Assessment of the Functional Role of Purified Antibodies from Asymptomatic P. vivax-infected Individuals from the Peruvian Amazon using P. Knowlesi in vitro Culture Model
Kobporn Boonnak, Siriraj Hospital, Mahidol University
Characterization of Neutralizing Versus Binding Antibody and T Cell Responses to Varicellar-zoster Virus in the Elderly
Characterization of Neutralizing Versus Binding Antibody and T Cell Responses to Varicellar-zoster Virus in the Elderly
On Own for Lunch
12:45–3:00 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
3:00–4:30 PM
Independence Salons ABCD
* Marie Pancera, Fred Hutchinson Cancer Center
Structural Basis for Antibody Cross-neutralization of Dengue and Zika Viruses
Structural Basis for Antibody Cross-neutralization of Dengue and Zika Viruses
Natacha Madelon, University of Geneva
Reactogenicity to mRNA Vaccines is Linked to Heightened Inflammatory Responses Driven by Vaccine-specific Antibody Responses and Host-intrinsic Factors
Reactogenicity to mRNA Vaccines is Linked to Heightened Inflammatory Responses Driven by Vaccine-specific Antibody Responses and Host-intrinsic Factors
Maya Sangesland, National Institutes of Health
Functional, Immunogenetic, and Structural Convergence in Influenza Immunity between Humans and Macaques
Functional, Immunogenetic, and Structural Convergence in Influenza Immunity between Humans and Macaques
Bo Zhang, Fred Hutchinson Cancer Center
CD4+ T Cell Responses to Vaccination in People with HIV Correlate with Risk of COVID-19 in the CoVPN 3008 Clinical Trial
CD4+ T Cell Responses to Vaccination in People with HIV Correlate with Risk of COVID-19 in the CoVPN 3008 Clinical Trial
Nicholas Cheang, National University of Singapore
Intranasal Dendritic Cell-targeting Vaccine Booster Elicits Cross-clade, Durable and Protective Systemic and Mucosal Immunity against Sarbecoviruses.
Intranasal Dendritic Cell-targeting Vaccine Booster Elicits Cross-clade, Durable and Protective Systemic and Mucosal Immunity against Sarbecoviruses.
* Sylvain Baize, Institut Pasteur
Immunogenicity and Efficacy of Vaccines against Crimean-Congo Hemorrhagic Fever Virus Based on Mopevac, a New Live-Attenuated Virus Vaccine Platform
Immunogenicity and Efficacy of Vaccines against Crimean-Congo Hemorrhagic Fever Virus Based on Mopevac, a New Live-Attenuated Virus Vaccine Platform
Coffee Available
4:30–5:00 PM
Foyer
Exploiting Tissue Specific Protection to Prevention and Cure
5:00–6:45 PM
Independence Salons ABCD
Yasmine Belkaid, Institut Pasteur
Immune Control of Host Physiology
Immune Control of Host Physiology
* Laurence Zitvogel, Institut Gustave Roussy
Gut Microbiota Impacts the Immunogenicity of Vaccines
Gut Microbiota Impacts the Immunogenicity of Vaccines
Christopher Chiu, Imperial College London
Clinical Trials for Intranasal and Aerosol SARS-CoV-2 Vaccine Development
Clinical Trials for Intranasal and Aerosol SARS-CoV-2 Vaccine Development
Kerrie Sandgren, Westmead Institute for Medical Research
Short Talk: Adjuvant As01 Activates an Innate Immune Cascade in Human Lymph Node Explants, Initiated by Subcapsular Sinus-Lining Macrophages, in an Age-Independent Manner
Short Talk: Adjuvant As01 Activates an Innate Immune Cascade in Human Lymph Node Explants, Initiated by Subcapsular Sinus-Lining Macrophages, in an Age-Independent Manner
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Independence Salons ABCD
Social Hour with Lite Bites
7:00–8:00 PM
Independence Salons EFGH
Trivia
8:00–9:00 PM
Independence Salons ABCD
Sunday, June 8, 2025
Departure
12:00–11:59 PM
Subscribe for Updates